Discovery of New Inhibitors of Hepatitis C Virus NS3/4A Protease and Its D168A Mutant by Ittipat Meewan (7455041)

“…Several drugs targeting the protease have been developed, but drug-resistant mutant strains emerged. Here, we screened a library and synthesized a novel class of small molecules based on a tryptophan derivative scaffold identified as HCV NS3/4A protease inhibitors that are active against both wild type and mutant form of the protease. …”

Changepoint analysis in comparison of MarBTN-specific eDNA and cancer in hemolymph. by Rachael M. Giersch (22331947)

Decreased echinocandin susceptibility in <i>Candida parapsilosis</i> causing candidemia and emergence of a pan-echinocandin resistant case in China by Yating Ning (11264310)

Variable importance plot (mean decrease accuracy and mean decrease Gini). by Fernando Martinez-Taboada (8655132)

Advancing the science of NOWS research. by Sarah E. Maylott (14560785)

“…<div><p>Every 15 minutes in the US, an infant exposed to opioids is born. Approximately 50% of these newborns will develop Neonatal Opioid Withdrawal Syndrome (NOWS) within 5 days of birth. …”

Protocol measures. by Sarah E. Maylott (14560785)

“…<div><p>Every 15 minutes in the US, an infant exposed to opioids is born. Approximately 50% of these newborns will develop Neonatal Opioid Withdrawal Syndrome (NOWS) within 5 days of birth. …”

Cry variables. by Sarah E. Maylott (14560785)

“…<div><p>Every 15 minutes in the US, an infant exposed to opioids is born. Approximately 50% of these newborns will develop Neonatal Opioid Withdrawal Syndrome (NOWS) within 5 days of birth. …”

Competition localization increases with growth rate or the distances between colonies, and decreases with the resource diffusion constant. by Jeremy M. Chacón (8259792)

DataSheet_1_Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2.pdf by Yun Ji (464484)

“…However, the continuous virus evolution requires diverse mAb options to combat variants. Here we describe two fully human mAbs, amubarvimab (BRII-196) and romlusevimab (BRII-198) that bind to non-competing epitopes on the receptor binding domain (RBD) of spike protein and effectively neutralize SARS-CoV-2 variants. …”

Decreasing fluconazole susceptibility of clinical South African <i>Cryptococcus neoformans</i> isolates over a decade by Serisha D. Naicker (8648370)

miR-200c decreases KLOTHO expression in HK-2 cells by translational repression. by Kenichi Morii (6843554)

The raw data for Fig 5B. by Hongjoo An (21703199)

“…This study applied the new method to <i>Sox10</i>, uncovering two OL enhancers for it (termed Sox10-E1 and Sox10-E2). Epigenome editing analysis revealed that Sox10-E1 and Sox10-E2 regulate <i>Sox10</i> expression non-redundantly. …”

Flow chart of the study procedures. by Kazuhiko Ikeuchi (9234268)

“…Pre-treatment spontaneous decrease of RPR titer was associated with a slower decrease in post-treatment RPR titer.…”

Prevalence and anatomic level of stenosis ≥ 50% in either limb. by O. Stivalet (6890189)

Discovery of the Triazolo[1,5‑<i>a</i>]Pyrimidine-Based Derivative WS-898 as a Highly Efficacious and Orally Bioavailable ABCB1 Inhibitor Capable of Overcoming Multidrug Resistance... by Shuai Wang (109515)

Subjects:

Discovery of the Triazolo[1,5‑<i>a</i>]Pyrimidine-Based Derivative WS-898 as a Highly Efficacious and Orally Bioavailable ABCB1 Inhibitor Capable of Overcoming Multidrug Resistance... by Shuai Wang (109515)

Subjects:

Repeated LSPC treatment prolongs survival of and decreases PrP^Res accumulation in a subset of prion-infected mice. by Heather Bender (363996)

Changes in 50-kHz USV duration (A-D) and amplitude (E-H) in rats with 7 (ABEF) or 14 (CDGH) training days during training (ACEG) and test (BDFH) sessions. by Agnieszka D. Wardak (17941139)

Data_Sheet_1_Microclimatic Warming Leads to a Decrease in Species and Growth Form Diversity: Insights From a Tropical Alpine Grassland.PDF by Sisimac A. Duchicela (11503918)

“…We installed five monitoring blocks in 2012 at ca. 4,200 m asl with 20 OTCs and 50 control plots randomly distributed within each block. …”

Olaparib reverses the oxLDL-mediated decrease in co-immunoprecipitation of IκBα with RelA or p50. by Khamis Mustafa (17941332)

“…Relative band densities from three independent experiments were analyzed. (A) OxLDL decreased co-immunoprecipitation of IκBα with both RelA and p50, and olaparib reversed the effect of oxLDL on the dissociation of IκBα with RelA and p50. …”